Received On: 10/07/2015
Accepted On: 19/07/2015
Talluri, M., Kurian, A.B., Adahalli, S.B.
Glibenclamide (GBM) belongs to BCS Class II category of poor solubility and poor bioavailability drug used for the treatment of non-insulin dependent Diabetes mellitus. Hence the oral absorption is dissolution rate limited and requires enhancement in the solubility and dissolution rate for increasing its oral bioavailability. Hence the main objective of this work was to formulate, develop and evaluate an optimal Self emulsifying drug delivery system (SEDDS) containing GBM. Solubility of Glibenclamide in oil, surfactant and co-surfactant was determined. Preliminary screening was carried out to select proper component combination. Glibenclamide SEDDS was prepared using Oleic acid (oil), Tween 80 (surfactant), PEG 400 (co-surfactant). A series of twenty one formulations were prepared. Tween 80 and PEG 400 were incorporated in the ratio1:1, 2:1 and 3:1 respectively for separate batches. Effects of lipids and surfactants on physical properties of SEDDS such as in vitro emulsification efficiency in terms of self-emulsification time, thermodynamic stability studies, Transmission electron microscopy (TEM), emulsion droplet size, and optical clarity were measured. Formulation F013 consisting of surfactant and co-surfactant ratio 1:2 exhibited the desired properties of ideal self-emulsifying drug delivery system ensuring the maximum dissolution property. The study revealed that higher amount of surfactants significantly increased dissolution of Glibenclamide while decreasing emulsion droplet size and emulsification time. About a four-fold increase in dissolution was achieved by SEDDS compared to pure GBM powder. Overall, the study suggests that dissolution and oral bioavailability of GBM could be improved by SEDDS technology.
SEDDS, Glibenclamide, Oleic acid, Tween 80, Polyethyleneglycol 400
Cite This Article
Talluri, M., Kurian, A.B., Adahalli, S.B. (2015). Formulation and Evaluation of Self Emulsifying Drug Delivery System of an Anti-diabetic Drug, International Journal for Pharmaceutical Research Scholars (IJPRS), 4(3), 150-162.